Matinas BioPharma ATM stock program terminated
Rhea-AI Filing Summary
Matinas BioPharma Holdings, Inc. reports that BTIG, LLC has terminated their At-The-Market Sales Agreement, which had allowed the company to offer and sell up to $50,000,000 of common stock in at-the-market offerings under Rule 415 of the Securities Act of 1933.
The termination, made pursuant to Section 12(a) of the Sales Agreement, became effective immediately on July 23, 2026. Matinas BioPharma states that it will not incur any termination penalties or other expenses in connection with ending this equity distribution arrangement.
Positive
- None.
Negative
- None.
Filing Explained
The filing ends the BTIG at-the-market route immediately; the separate June 16 S-3 shelf contemplated up to
8-K Event Classification
Item 1.02 — Termination of a Material Definitive Agreement
1 item
Item 1.02
Termination of a Material Definitive Agreement
Business
A significant contract was terminated, which may affect business operations or revenue.
Key Figures
ATM Program Size: $50,000,000
Par Value per Share: $0.0001
Termination Date: July 23, 2026
+1 more
4 metrics
ATM Program Size
$50,000,000
Aggregate offering price of common stock under At-The-Market Sales Agreement with BTIG
Par Value per Share
$0.0001
Par value of Matinas BioPharma common stock referenced in the Sales Agreement
Termination Date
July 23, 2026
Date BTIG terminated the At-The-Market Sales Agreement under Section 12(a)
Original Agreement Date
July 2, 2020
Date Matinas BioPharma entered into the At-The-Market Sales Agreement with BTIG
Key Terms
At-The-Market Sales Agreement, at-the-market offerings, Rule 415 of the Securities Act of 1933, Emerging growth company
4 terms
At-The-Market Sales Agreement financial
"entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with BTIG"
An at-the-market sales agreement lets a company raise cash by selling newly issued shares directly into the open market at whatever price buyers are paying that day, using a broker to place the trades over time. Investors should watch these deals because they can dilute existing ownership and put downward pressure on the stock price while giving the company flexible, on-demand funding—like a store gradually listing extra items on an online marketplace at current prices.
at-the-market offerings financial
"sell shares of its common stock ... through BTIG in “at-the-market offerings”"
An at-the-market offering is a method for a company to sell new shares of its stock directly into the stock market over time, rather than all at once. This approach allows the company to raise money gradually, similar to selling small portions of a product as demand grows. For investors, it can influence stock availability and price, making it an important factor to consider when assessing a company's financial strategy.
Rule 415 of the Securities Act of 1933 regulatory
"“at-the-market offerings” as defined in Rule 415 of the Securities Act of 1933"
Emerging growth company regulatory
"Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Matinas BioPharma (MTNB) disclose about its agreement with BTIG?
Matinas BioPharma disclosed that BTIG, LLC terminated their At-The-Market Sales Agreement effective July 23, 2026. This agreement had allowed Matinas to sell common stock in at-the-market offerings, up to an aggregate amount of $50,000,000, through BTIG.
How large was the Matinas BioPharma (MTNB) at-the-market program with BTIG?
The At-The-Market Sales Agreement with BTIG allowed Matinas BioPharma to sell up to $50,000,000 of common stock. These shares could be offered from time to time in at-the-market offerings as defined under Rule 415 of the Securities Act of 1933.
When did BTIG terminate the Matinas BioPharma (MTNB) At-The-Market Sales Agreement?
BTIG terminated the Matinas BioPharma At-The-Market Sales Agreement effective July 23, 2026. The termination was made pursuant to Section 12(a) of the Sales Agreement and became effective immediately upon BTIG’s notice to the company on that date.
Does Matinas BioPharma (MTNB) owe penalties due to the BTIG agreement termination?
Matinas BioPharma states it is not subject to any termination penalties or other expenses related to BTIG ending the Sales Agreement. The termination therefore removes the at-the-market facility without imposing additional financial obligations tied to its cancellation.
What type of offerings were permitted under Matinas BioPharma’s (MTNB) BTIG agreement?
The BTIG agreement permitted Matinas BioPharma to conduct “at-the-market offerings” of its common stock. These offerings, defined under Rule 415 of the Securities Act of 1933, allow issuers to sell shares into the market from time to time.
When was the original At-The-Market Sales Agreement between Matinas BioPharma (MTNB) and BTIG signed?
Matinas BioPharma originally entered into the At-The-Market Sales Agreement with BTIG on July 2, 2020. From that date, the company was able to offer and sell its common stock through BTIG, subject to the $50,000,000 aggregate offering limit.
AI-generated analysis. How Rhea-AI works. Not financial advice.
